1 published article · Updated continuously
22 trials tracked for Primary Peritoneal Cancer: 2 in phase 3 or 4 and 1 with published results. The most-cited published study has 20 citations.
Showing the 22 most-cited and recently-updated of 22 trials. Browse the full registry →
Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.
Paclitaxel treatment in patients with primary peritoneal cancer is associated with statistically significant improvements in progression-free survival (PFS) 1. Clinical observations also indicate that Paclitaxel is associated with improvements in patient-reported abdominal pain (ranging from 31.3% to 48.4%) and bloating (ranging from 26.1% to 47.4%) 1. However, other trials evaluating Paclitaxel did not find a statistically significant difference in 6-month progression-free survival rates 2 or overall survival 2.
Carboplatin has been evaluated in clinical settings for this condition 20, and its administration was associated with specific quality of life (QOL) scores 5.
Niraparib was evaluated in a Phase 2 trial, where 17 participants experienced Grade 3 or higher treatment-emergent adverse events (TEAEs) 7. In a separate trial, 14 participants experienced Grade 3 or higher TEAEs, and 6 participants experienced Grade 3 or 4 thrombocytopenia within 30 days of initial administration 8.
Bevacizumab has been established in clinical trials for this condition [14, 15].
AI synthesis of 7 cited trials, updated Sep 19, 2026. Informational only — not medical advice; trial data sourced from ClinicalTrials.gov. How we use AI.
